🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On #MartinLutherKingDay, the flock is encouraged to spend the day reflecting on and celebrating the life and legacy of the Reverend Dr. Martin Luther King, Jr. We encourage you to also take the time to commemorate his work in the fight for civil rights, freedom, and equality.

Bringing more bluebird days to patients and caregivers impacted by rare diseases is #whywefly. On #RareDiseaseDay, Christina Hartman, Head of Government Affairs and rare mom, shares why she flies for her daughter Charlotte, her community of support, & everyone in the #raredisease

We’re extremely pleased to announce that bluebird bio has signed our first Medicaid outcomes-based agreement for sickle cell disease gene therapy with the state of Michigan.   Approximately 50 percent of individuals living with sickle cell disease in the U.S. are insured by

#NewsFromTheNest: Join the bluebird team as they discuss fourth quarter and 2023 annual results and provide a commercial update on Tuesday, March 26 at 8:00 a.m. ET. Learn more: investor.bluebirdbio.com/news-releases/…

Thank you, MassBio, for featuring bluebird bio as the April MassBio Member Spotlight and for highlighting our leadership and the way the flock keeps patients and families at the heart of everything we do.

Today, bluebird bio announces the first person living with sickle cell has initiated treatment with our sickle cell disease gene therapy in the commercial setting. Andrew Obenshain, chief executive officer, shares his reflection on this milestone: “Seeing people living with

Today, bluebird bio reported first quarter 2024 results and business highlights, including the update that we have completed the first commercial cell collection for our sickle cell disease gene therapy. Learn more: investor.bluebirdbio.com/news-releases/…

Today, bluebird bio occupies a unique space as a standalone commercial gene therapy company. We are excited to share perspective from a decade of gene therapy leadership and continue learning from other pioneers in the field at #BIO2024. Come say hi if you’ll be in San Diego

Each journey with sickle cell disease is unique. This #WorldSickleCellDay, learn more about Charlotte’s story and how she advocates for the sickle cell community: Meet Charlotte, living with sickle cell disease: youtu.be/f5U1mroyxUw

Today, bluebird bio announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for #sicklecell gene therapy under the Cell and Gene Therapy (CGT) Access Model.   “Ensuring timely, equitable access to

Today bluebird bio announced a definitive agreement to be acquired by Carlyle and SK Capital. Read more in our press release: investor.bluebirdbio.com/news-releases/…